Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 29, Issue 35, 2011, Pages 4662-4668

  Konner, Jason A ^a   Grabon, Diana M ^a   Gerst, Scott R ^a   Iasonos, Alexia ^a   Thaler, Howard ^a   Pezzulli, Sandra D ^a   Sabbatini, Paul J ^a   Bell McGuinn, Katherine M ^a   Tew, William P ^a   Hensley, Martee L ^a   Spriggs, David R ^a   Aghajanian, Carol A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ABDONIAL PAIN; ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANASTOMOSIS DEHISCENCE; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LEUKOPENIA; LYMPHOCYTOPENIA; MOUTH INFECTION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; NOSE DISEASE; OVARY CANCER; PATIENT COMPLIANCE; PERITONITIS; PHARYNX DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR PERFORATION; VAGINA DISEASE; VAGINA IRRITATION; VOICE CHANGE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PILOT PROJECTS;

EID: 83355169742     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1352     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003 (Pubitemid 46606249)
3. Alberts DS, Liu PY, Hannigan EV, et al: Phase III study of intraperitoneal cisplatin-intravenous cyclophosphamide versus intravenous cisplatinintravenous cyclophosphamide in patients with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG Intergroup study. Int J Gynecol Cancer 6:28-29, 1996 (Pubitemid 26272394)
4. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001 (Pubitemid 32176274)
5. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996 (Pubitemid 26012496)
6. Walker JL, Armstrong DK, Huang HQ, et al: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 100:27-32, 2006 (Pubitemid 41815045)
7. Alvarez AA, Krigman HR, Whitaker RS, et al: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587-591, 1999 (Pubitemid 29131968)
8. Hollingsworth HC, Kohn EC, Steinberg SM, et al: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-41, 1995
9. Paley PJ, Staskus KA, Gebhard K, et al: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106, 1997 (Pubitemid 27270925)
10. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997 (Pubitemid 27441066)
11. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
12. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
13. Penson RT, Dizon DS, Cannistra SA, et al: Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28:154-159, 2009
14. Burger RA, Brady MF, Bookman MA, et al: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28:5s, 2010 (suppl; abstr LBA1)
15. Perren T, Swart AM, Pfisterer J, et al: ICON7: A phase III randomized gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab versus chemotherapy alone in women with newly diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The 35th European Society for Medical Oncology (ESMO) Congress, Milan, Italy, October 8-12, 2010 (abstr LBA4)
16. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996 (Pubitemid 26428219)
17. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006 (Pubitemid 43048949)
18. Fleming GF, Fowler JM, Waggoner SE, et al: Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: A Gynecologic Oncology Group study. J Clin Oncol 19:1021-1029, 2001 (Pubitemid 32176277)
19. Ferguson SE, Black D, Chi DS, et al: Toxicities of modified outpatient regimen of IV/IP paclitaxel and IP cisplatin in women with newly diagnosed ovarian cancer. Plenary presentation at the 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007
20. McMeekin DD, Lanneau G, Curiel J, et al: Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers. J Clin Oncol 27:287s, 2009 (suppl; abstr 5540)